

Issues and Insights

JANUARY EDITION

Welcome to the latest issue of Issues and Insights, summarizing our latest thinking on subjects affecting your business. Use the information to stay resilient and grow through these disruptive times.

Hot topics



How life sciences can meet increased FCPA, anti-corruption enforcement

In a recent roundtable, KPMG senior forensic professionals explained trends in authorities' anti-corruption enforcement approaches and offered suggestions for designing, implementing, monitoring, and updating an anti-corruption framework that ensures compliance with all applicable rules and regulations.



Implementing the healthcare future: Where do you stand?

Healthcare organizations report good results from their digital transformation initiatives, particularly around automation, artificial intelligence (AI) and machine learning. But what else are they looking for? And how does your organization compare with your peers? [Get the answers here.](#)



Home Sales: Beware of cancellations

The Federal Reserve's tightening hit the interest sensitive housing market the hardest of all sectors. A fall in national home values will be the next shoe to drop. However, we expect those shifts to reverse in the second half of the year, as rates peak and the market becomes more affordable.



Durable goods orders better than they look

The drop in November durable goods orders overstates the pessimism in business plans, but the downward momentum in core capital goods is likely to continue in the first half of 2023. We know the Federal Reserve's job to tame inflation is not done. [What will additional rate hikes do to GDP – and you?](#)



Generic Drugs: Maximizing the Potentials for Portfolio Strategy

The passing of the Inflation Reduction Act (IRA) in August 2022 may create a more attractive market for generic drug manufacturers to consider innovate portfolio strategy management. The Department of Health and Human services will have the ability to negotiate drug prices, creating a significant impact on the way drug producers choose to commercialize products and invest in R & D. [What are the 3 key strategies drug companies can take to maintain viability?](#)



Corporate boards: Key missions for the year ahead

The business and risk environment has changed dramatically in the past year, with geopolitical instability, surging inflation, and potential recession among the highlights. [See how boards are setting their agendas, defining their challenges, and meeting their expanding responsibilities going forward.](#)



The ten regulatory challenges you'll face in '23

All signs point to increased supervision, enforcement, and investigations in the year ahead, as regulators pursue "weak links" within risk programs and coverage. Expect regulators to focus on scrutiny and divergence, climate and sustainability, tech and resilience, fraud, crypto and more. [Get the skinny on the 10 categories primed for close examination – and the steps you should take to prepare.](#)



Digital to the core!

The 2022 KPMG U.S. Technology Survey Report highlights the rapid adoption of new digital technologies in all sectors of the U.S. economy. The responses of 1,052 executive-level technology professionals in public, private, and government organizations provide a detailed picture of the aggressive steps being taken in the rush to digital transformation. [Get the full report here.](#)

kpmg.com/socialmedia



The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation.

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. NDP421446-4A